Key facts
- It has raised $1.8M; the latest was Seed Round ($1.8M) in Feb 2025.
- Notable investors include BioIntelligence, Capacura, Fonde Ventures, Life Science Factory, NBank Capital — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Phaeosynt
- ·The full record, as it builds
Funding rounds
No funding rounds for Phaeosynt are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phaeosynt
Developer of vegan antibodies from diatoms designed to protect the environment and animal welfare. The company platform offers vegan-certified diagnostics, which offer an animal-free alternative to conventional antibodies from cell cultures, enabling clients with a new alternative for climate-neutral antibody production on an industrial scale.
- Sector
- Healthcare
- HQ
- Hanover, Germany
- Founded
- 2021
- Employees
- 10
- Website
- phaeosynt.com/
- Ownership
- Privately Held (backing)
Phaeosynt doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phaeosynt shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phaeosynt in its N-PORT filings yet. We sweep new filings monthly.